AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30897038 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab
Number of subjects: 358
Study 30897038 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus rituximab
Number of subjects: 358
Study 27702806 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% fluoride gel application
Number of subjects: 46
Study 27702806 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel application
Number of subjects: 46
Study 26496331 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter device (oscillating positive expiratory pressure)
Number of subjects: 15
Study 23621629 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS) with delayed withdrawal (intra-operative methylprednisolone weaned by six months)
Number of subjects: 39
Study 23621629 — intervention group
Group type: COMPARATOR
Intervention: CS-free regimen with basiliximab, tacrolimus, and enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 39
Study 23621629 — intervention group
Group type: COMPARATOR
Intervention: Both CS and CS-free groups
Number of subjects: 39
Study 21536191 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy rotational force (225 g)
Number of subjects: 15
Study 21536191 — intervention group
Group type: COMPARATOR
Intervention: Light rotational force (25 g)
Number of subjects: 15
Study 21536191 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy rotational forces
Number of subjects: 15
Study 21536191 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression areas (buccal‐distal and lingual‐mesial surfaces)
Number of subjects: 15
Study 19702208 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg x kg(‐1) IV fentanyl
Number of subjects: 318
Study 19702208 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 microg x kg(‐1) IV fentanyl
Number of subjects: 318
Study 19702208 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg x kg(‐1) IV fentanyl
Number of subjects: 318
Study 16720765 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee replacement with cemented polyethylene patellar component
Number of subjects: 100
Study 16720765 — intervention group
Group type: COMPARATOR
Intervention: Total knee replacement without cemented polyethylene patellar component
Number of subjects: 100
Study 15663094 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (CDDP+FU, TAX+FU, CDDP)
Number of subjects: 70
Study 15663094 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment only (Control group)
Number of subjects: 70
Study 11468047 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural programme
Number of subjects: 610
Study 11468047 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention
Number of subjects: 610
Study 11468047 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 610
Study 9639767 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (50 micrograms intra‐vaginally every 3 hours until active labor)
Number of subjects: 60
Study 9639767 — intervention group
Group type: COMPARATOR
Intervention: Ricinus oil meal
Number of subjects: 60
Study 9639767 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 60
Study 8480881 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 363
Study 8480881 — intervention group
Group type: COMPARATOR
Intervention: Mini-cholecystectomy
Number of subjects: 363
Study 3111702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 3 mg dihydroergocristine and 100 mg levo‐5‐hydroxytryptophan
Number of subjects: 50
Study 3111702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30308200 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor cornea with preservation time (PT) of 0-7 days
Number of subjects: 1090
Study 30308200 — intervention group
Group type: COMPARATOR
Intervention: Donor cornea with preservation time (PT) of 8-14 days
Number of subjects: 1090
Study 30308200 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts that experienced rejection (n=27)
Number of subjects: 1090
Study 30308200 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts that did not experience rejection (n=886)
Number of subjects: 1090
Study 30308200 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite graft rejection (n=12 of 44 eyes)
Number of subjects: 1090
Study 27498100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 100
Study 27498100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 50 mg
Number of subjects: 100
Study 27498100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24852180 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 36
Study 24852180 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 36
Study 23071204 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus reuteri, 5 drops containing 10^8 CFU)
Number of subjects: 750
Study 23071204 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 750
Study 20600033 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic tri-modal imaging (ETMI)
Number of subjects: 87
Study 20600033 — intervention group
Group type: COMPARATOR
Intervention: Standard video endoscopy (SVE)
Number of subjects: 87
Study 20600033 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic tri-modal imaging (ETMI) with detailed inspection using narrow band imaging (NBI)
Number of subjects: 87
Study 17850684 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.75 microg kg(‐1) (Group 2)
Number of subjects: 124
Study 17850684 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg kg(‐1) (Group 3)
Number of subjects: 124
Study 17850684 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1.25 microg kg(‐1) (Group 4)
Number of subjects: 124
Study 17850684 — intervention group
Group type: COMPARATOR
Intervention: normal saline (Group 1)
Number of subjects: 124
Study 15220247 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose trandolapril-verapamil (FDTV) 2 mg trandolapril/180 mg verapamil once daily
Number of subjects: 60
Study 15220247 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril 2 mg once daily
Number of subjects: 60
Study 15220247 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril
Number of subjects: 60
Study 15220247 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose trandolapril-verapamil (FDTV)
Number of subjects: 60
Study 11576097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam 0.1 microg x kg(‐1) x min(‐1) (n = 16)
Number of subjects: 31
Study 11576097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 31
Study 11576097 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 9850900 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 units of the immunotoxin MDX‐RA
Number of subjects: 63
Study 9850900 — intervention group
Group type: EXPERIMENTAL
Intervention: 175 units of the immunotoxin MDX‐RA
Number of subjects: 63
Study 9850900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 8010427 — intervention group
Group type: EXPERIMENTAL
Intervention: Active aspiration (AA)
Number of subjects: 40
Study 8010427 — intervention group
Group type: COMPARATOR
Intervention: Nonactive aspiration (NAA)
Number of subjects: 40
Study 2802896 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (75 mg/kg per day, capsule form, three times daily for 24 weeks)
Number of subjects: 108
Study 2802896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (capsule form, three times daily for 24 weeks)
Number of subjects: 108
Study 2802896 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 108
Study 2802896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 869054 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 12
Study 869054 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline
Number of subjects: 12
Study 869054 — intervention group
Group type: EXPERIMENTAL
Intervention: Deanol
Number of subjects: 12
Study 869054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31515355 — intervention group
Group type: EXPERIMENTAL
Intervention: MPT-T (melphalan-prednisolone + thalidomide)
Number of subjects: 596
Study 31515355 — intervention group
Group type: EXPERIMENTAL
Intervention: MPR-R (melphalan-prednisolone + lenalidomide)
Number of subjects: 596
Study 31515355 — intervention group
Group type: EXPERIMENTAL
Intervention: MPT-T
Number of subjects: 596
Study 31515355 — intervention group
Group type: EXPERIMENTAL
Intervention: MPR-R
Number of subjects: 596
Study 31515355 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 596
Study 31515355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MPT-T and MPR-R
Number of subjects: 596
Study 31546498 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: Low parameters (AFR = 20 cc/min, BH = 90 cm, vacuum = 400 mmHg)
Number of subjects: 20
Study 31546498 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: High parameters (AFR = 40 cc/min, BH = 110 cm, vacuum = 650 mmHg)
Number of subjects: 20
Study 28599034 — intervention group
Group type: EXPERIMENTAL
Intervention: Procellera® applied topically two to three times per week for 2 weeks
Number of subjects: 80
Study 28599034 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) treatment, moleskin and Tegaderm®
Number of subjects: 80
Study 28599034 — intervention group
Group type: EXPERIMENTAL
Intervention: Procellera®
Number of subjects: 80
Study 28599034 — intervention group
Group type: EXPERIMENTAL
Intervention: Procellera® and SOC
Number of subjects: 80
Study 28599034 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) treatment
Number of subjects: 80
Study 25935299 — intervention group
Group type: EXPERIMENTAL
Intervention: €12.50 monetary incentive
Number of subjects: 0
Study 25935299 — intervention group
Group type: COMPARATOR
Intervention: €7.50 monetary incentive
Number of subjects: 0
Study 25935299 — intervention group
Group type: COMPARATOR
Intervention: €10.00 monetary incentive
Number of subjects: 0
Study 22678407 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure wristband
Number of subjects: 120
Study 22678407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 21724041 — intervention group
Group type: EXPERIMENTAL
Intervention: Humorous video
Number of subjects: 46
Study 21724041 — intervention group
Group type: COMPARATOR
Intervention: Neutral video
Number of subjects: 46
Study 21724041 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense of humor
Number of subjects: 46
Study 19657846 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow freezing
Number of subjects: 0
Study 19657846 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification
Number of subjects: 0
Study 16490895 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (sugarless gum 3 times daily for 1 hour each until discharge)
Number of subjects: 34
Study 16490895 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 34
Study 15360122 — intervention group
Group type: EXPERIMENTAL
Intervention: Feigned depression condition
Number of subjects: 22
Study 15360122 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 22
Study 11323373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume breathing (TVB) for 3-5 min at 5, 7, and 10 L/min fresh gas flow (FGF)
Number of subjects: 24
Study 11323373 — intervention group
Group type: EXPERIMENTAL
Intervention: Four deep breaths (DB) in 0.5 min at 5, 7, and 10 L/min FGF
Number of subjects: 24
Study 11323373 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight deep breaths (DB) in 1 min at 7 and 10 L/min FGF
Number of subjects: 24
Study 11323373 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing extended to 1.5 and 2 min with 10 L/min FGF
Number of subjects: 24
Study 11323373 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TVB and DB techniques
Number of subjects: 24
Study 11323373 — intervention group
Group type: COMPARATOR
Intervention: Increasing FGF from 5 to 10 L/min
Number of subjects: 24
Study 9209004 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (5 x 500 U/kg bodyweight intravenously over 14 days preoperatively)
Number of subjects: 72
Study 9209004 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously over 14 days preoperatively)
Number of subjects: 72
Study 7962395 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (VITA) at 1 microM for 16 hours
Number of subjects: 3
Study 7962395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigasone (etretinate, TIG) at 1 microM for 16 hours
Number of subjects: 3
Study 7962395 — intervention group
Group type: EXPERIMENTAL
Intervention: Roaccutane (isotretinoin, ROA) at 1 microM for 16 hours
Number of subjects: 3
Study 7962395 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A (VITA), Tigasone (TIG), Roaccutane (ROA) at 1 microM for 16 hours
Number of subjects: 3
Study 3578544 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 0
Study 3578544 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 0
Study 3578544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31633161 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin mass drug administration (MDA)
Number of subjects: 0
Study 31633161 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated azithromycin MDA
Number of subjects: 0
Study 31633161 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard microbiological techniques
Number of subjects: 0
Study 31633161 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted short-term and long-term surveillance
Number of subjects: 0
Study 29393208 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methadone dose adjustments to reach plasma R-methadone levels (80-250 ng/mL)
Number of subjects: 0
Study 29393208 — intervention group
Group type: COMPARATOR
Intervention: Plasma R-methadone levels in the target range at the beginning of the study
Number of subjects: 0
Study 29393208 — intervention group
Group type: COMPARATOR
Intervention: Maintaining plasma R-methadone target levels (per protocol analysis)
Number of subjects: 0
Study 27514345 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 0
Study 27514345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24916132 — intervention group
Group type: EXPERIMENTAL
Intervention: Food with gadget (Toy)
Number of subjects: 1680
Study 24916132 — intervention group
Group type: COMPARATOR
Intervention: Food alone (No Toy)
Number of subjects: 1680
Study 23702779 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical natamycin
Number of subjects: 0
Study 23702779 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 0
Study 20795751 — intervention group
Group type: EXPERIMENTAL
Intervention: Menveo vaccine
Number of subjects: 0
Study 19052709 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0
Study 19052709 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapeutic hypothermia)
Number of subjects: 0
Study 16881934 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged thromboprophylaxis with dalteparin (5000 IU once daily for 28 days)
Number of subjects: 590
Study 16881934 — intervention group
Group type: COMPARATOR
Intervention: Short-term thromboprophylaxis (dalteparin for 7 days)
Number of subjects: 590
Study 16881934 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged thromboprophylaxis with dalteparin
Number of subjects: 590
Study 12832673 — intervention group
Group type: EXPERIMENTAL
Intervention: gemifloxacin 320 mg once daily for 5 days
Number of subjects: 438
Study 12832673 — intervention group
Group type: COMPARATOR
Intervention: clarithromycin 500 mg twice daily for 7 days
Number of subjects: 438
Study 12832673 — intervention group
Group type: EXPERIMENTAL
Intervention: no further exacerbations
Number of subjects: 438
Study 11219600 — intervention group
Group type: EXPERIMENTAL
Intervention: Wall Motion (WM) assessment using gated SPECT
Number of subjects: 44
Study 11219600 — intervention group
Group type: EXPERIMENTAL
Intervention: Wall Thickening (WT) assessment using gated SPECT
Number of subjects: 44
Study 11219600 — intervention group
Group type: EXPERIMENTAL
Intervention: Wall Motion (WM) assessment
Number of subjects: 44
Study 11219600 — intervention group
Group type: EXPERIMENTAL
Intervention: Wall Thickening (WT) assessment
Number of subjects: 44
Study 9072891 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of antioxidants in combined treatment of schizophrenic patients
Number of subjects: 185
Study 9072891 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 185
Study 1386823 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO‐3708 (3 micrograms.kg‐1.min‐1)
Number of subjects: 15
Study 1386823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3921278 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (up to 360 mg daily)
Number of subjects: 24
Study 3921278 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus maximum tolerated dose of diltiazem
Number of subjects: 24
Study 3921278 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 24
Study 3921278 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 24
Study 3921278 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diltiazem and propranolol
Number of subjects: 24
Study 31402081 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental exercise (phonation into a resonance flexible tube in water)
Number of subjects: 30
Study 31402081 — intervention group
Group type: COMPARATOR
Intervention: Control exercise (tongue trill exercise)
Number of subjects: 30
Study 31402081 — intervention group
Group type: COMPARATOR
Intervention: Placebo exercise (unvoiced fricative exercise)
Number of subjects: 30
Study 26726854 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief positive psychotherapy plus usual treatment
Number of subjects: 27
Study 26726854 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment only
Number of subjects: 27
Study 26726854 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief positive psychotherapy
Number of subjects: 27
Study 27040694 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased water consumption by 1 glass/d
Number of subjects: 1987
Study 27040694 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of sugar-containing beverages by 1 glass/d
Number of subjects: 1987
Study 27040694 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of water consumption
Number of subjects: 1987
Study 24532596 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extension constraint training for 4 weeks
Number of subjects: 24
Study 22795046 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy coupled with cognitive behavioral therapy (MET‐CBT)
Number of subjects: 168
Study 22795046 — intervention group
Group type: COMPARATOR
Intervention: Brief advice
Number of subjects: 168
Study 19540739 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (3g/day) for 2 months
Number of subjects: 81
Study 19540739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 18499526 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 8
Study 17512361 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidetector computed tomography (MDCT)
Number of subjects: 200
Study 17512361 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary angiography
Number of subjects: 200
Study 15586800 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC 0.05% (4 x 200 microL/day for 8 days)
Number of subjects: 16
Study 15586800 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC 0.05%
Number of subjects: 16
Study 11530146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase plus enoxaparin
Number of subjects: 6095
Study 11530146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase plus abciximab
Number of subjects: 6095
Study 9266876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime, 1.5 g IV tid for 48 to 72 h followed by oral cefuroxime axetil, 500 mg bid for 7 days
Number of subjects: 636
Study 9266876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime, 1.5 g IV bid for 48 to 72 h followed by oral cefuroxime axetil, 500 mg bid for 7 days
Number of subjects: 636
Study 8302152 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous succinylcholine infusion
Number of subjects: 15
Study 8302152 — intervention group
Group type: COMPARATOR
Intervention: Single-dose technique
Number of subjects: 15
Study 3557014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 283
Study 3557014 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 283
Study 31472028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 312
Study 31472028 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 312
Study 27334521 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring of home blood pressure measurements (TBPM)
Number of subjects: 375
Study 27334521 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 375
Study 25514585 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-intervention group (debriefed after scenario sets)
Number of subjects: 67
Study 25514585 — intervention group
Group type: COMPARATOR
Intervention: Simulation exposure-only group
Number of subjects: 67
Study 25514585 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 22889466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-umbilical injection of oxytocin (50 IU diluted with normal saline to a total volume of 30 mL)
Number of subjects: 58
Study 22889466 — intervention group
Group type: COMPARATOR
Intervention: Intra-umbilical injection of normal saline (30 mL)
Number of subjects: 58
Study 21277062 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam and 1‐mg/kg tramadol
Number of subjects: 60